Literature DB >> 14612600

Prostate cancer management: (1) an update on localised disease.

S R J Bott1, A J Birtle, C J Taylor, R S Kirby.   

Abstract

Prostate cancer is receiving ever more publicity with the result that more men are having their prostate specific antigen checked and a greater proportion of men are diagnosed with potentially curable localised disease. Advances in the therapeutic modalities including radical surgery, external beam radiotherapy, and brachytherapy have reduced the incidence of side effects and now offer patients a choice of treatments depending on their tumour characteristics, age, and co-morbidity. A significant proportion of men do not need intervention and may be safely kept under a "watch and wait" policy. The use of genetic markers may in the future distinguish between patients most likely to benefit from radical therapy and those in who either palliation or observation is more appropriate. This review examines the potentially curative options, as well as expectant management, outlining the pros and cons of each. The use of adjuvant and neoadjuvant therapy is also discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14612600      PMCID: PMC1742848          DOI: 10.1136/pmj.79.936.575

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  62 in total

1.  Laparoscopic radical prostatectomy: preliminary results.

Authors:  C C Abbou; L Salomon; A Hoznek; P Antiphon; A Cicco; F Saint; W Alame; J Bellot; D K Chopin
Journal:  Urology       Date:  2000-05       Impact factor: 2.649

2.  Laparoscopic radical prostatectomy: the Montsouris technique.

Authors:  B Guillonneau; G Vallancien
Journal:  J Urol       Date:  2000-06       Impact factor: 7.450

Review 3.  Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel.

Authors:  J D Cox; M J Gallagher; E H Hammond; R S Kaplan; P F Schellhammer
Journal:  J Clin Oncol       Date:  1999-04       Impact factor: 44.544

4.  Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in Sweden.

Authors:  J Hugosson; G Aus; C Becker; S Carlsson; H Eriksson; H Lilja; P Lodding; G Tibblin
Journal:  BJU Int       Date:  2000-06       Impact factor: 5.588

5.  Patterns of treatment of patients with prostate cancer initially managed with surveillance: results from The CaPSURE database. Cancer of the Prostate Strategic Urological Research Endeavor.

Authors:  T M Koppie; G D Grossfeld; D Miller; J Yu; D Stier; J M Broering; D Lubeck; J M Henning; S C Flanders; P R Carroll
Journal:  J Urol       Date:  2000-07       Impact factor: 7.450

6.  PSA based review of adjuvant and salvage radiation therapy vs. observation in postoperative prostate cancer patients.

Authors:  R E Peschel; T J Robnett; D Hesse; C R King; R D Ennis; P B Schiff; L D Wilson
Journal:  Int J Cancer       Date:  2000-02-20       Impact factor: 7.396

7.  The efficacy of early adjuvant radiation therapy for pT3N0 prostate cancer: a matched-pair analysis.

Authors:  R K Valicenti; L G Gomella; M Ismail; S E Strup; S G Mulholland; A P Dicker; R O Petersen; C J Newschaffer
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-08-01       Impact factor: 7.038

8.  Radiotherapy after radical prostatectomy: treatment outcomes and failure patterns.

Authors:  D M Nudell; G D Grossfeld; V K Weinberg; M Roach; P R Carroll
Journal:  Urology       Date:  1999-12       Impact factor: 2.649

9.  Radical retropubic prostatectomy: bladder neck preservation versus reconstruction.

Authors:  M Poon; H Ruckle; B R Bamshad; C Tsai; R Webster; P Lui
Journal:  J Urol       Date:  2000-01       Impact factor: 7.450

10.  Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer.

Authors:  P C Albertsen; J A Hanley; D F Gleason; M J Barry
Journal:  JAMA       Date:  1998-09-16       Impact factor: 56.272

View more
  6 in total

Review 1.  Managing the low-socioeconomic-status prostate cancer patient.

Authors:  Walter Rayford
Journal:  J Natl Med Assoc       Date:  2006-04       Impact factor: 1.798

2.  [Effects of modified inclusion criteria and negative reporting about PSA screening on the number of potentially recruitable patients for the PREFERE study].

Authors:  J Mathes; M Burger; J E Gschwend; O W Hakenberg; S Krege; J Lehmann; K Miller; J Roigas; S Roth; T Kälble
Journal:  Urologe A       Date:  2016-09       Impact factor: 0.639

Review 3.  Prostate cancer management: 2. An update on locally advanced and metastatic disease.

Authors:  S R J Bott; A J Birtle; C J Taylor; R S Kirby
Journal:  Postgrad Med J       Date:  2003-11       Impact factor: 2.401

Review 4.  Active surveillance or active treatment in localized prostate cancer?

Authors:  Lothar Weissbach; Jens Altwein
Journal:  Dtsch Arztebl Int       Date:  2009-05-29       Impact factor: 5.594

5.  Interrupted versus continuous suturing for vesicourethral anastomosis during radical prostatectomy: protocol for a systematic review and meta-analysis.

Authors:  Karl Friedrich Kowalewski; Christian Tapking; Svetlana Hetjens; Felix Nickel; Philipp Mandel; Manuel Ritter; Maximilian Christian Kriegmair
Journal:  BMJ Open       Date:  2017-11-25       Impact factor: 2.692

6.  The Role of lncRNAs TAPIR-1 and -2 as Diagnostic Markers and Potential Therapeutic Targets in Prostate Cancer.

Authors:  Maik Friedrich; Karolin Wiedemann; Kristin Reiche; Sven-Holger Puppel; Gabriele Pfeifer; Ivonne Zipfel; Stefanie Binder; Ulrike Köhl; Gerd A Müller; Kurt Engeland; Achim Aigner; Susanne Füssel; Michael Fröhner; Claudia Peitzsch; Anna Dubrovska; Michael Rade; Sabina Christ; Stephan Schreiber; Jörg Hackermüller; Jörg Lehmann; Marieta I Toma; Michael H Muders; Ulrich Sommer; Gustavo B Baretton; Manfred Wirth; Friedemann Horn
Journal:  Cancers (Basel)       Date:  2020-04-30       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.